Literature DB >> 12395908

Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis.

Hiroyuki Hanai1, Fumitoshi Watanabe, Abby R Saniabadi, Isao Matsushitai, Ken Takeuchi, Takayuki Iida.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 12395908     DOI： 10.1023/a:1020159932758

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  18 in total

1.  A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis.

Authors:  N Kashiwagi; I Hirata; R Kasukawa
Journal:  Ther Apher       Date:  1998-05

2.  Clinical remission in Crohn's disease--assessment using faecal 111In granulocyte excretion.

Authors:  S H Saverymuttu
Journal:  Digestion       Date:  1986       Impact factor: 3.216

Review 3.  Alterations of the immune system in ulcerative colitis and Crohn's disease.

Authors:  R P MacDermott; W F Stenson
Journal:  Adv Immunol       Date:  1988       Impact factor: 3.543

4.  Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy.

Authors:  P J Limburg; D A Ahlquist; W J Sandborn; D W Mahoney; M E Devens; J J Harrington; A R Zinsmeister
Journal:  Am J Gastroenterol       Date:  2000-10       Impact factor: 10.864

5.  Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease.

Authors:  J A Tibble; G Sigthorsson; S Bridger; M K Fagerhol; I Bjarnason
Journal:  Gastroenterology       Date:  2000-07       Impact factor: 22.682

6.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Authors:  D Rachmilewitz
Journal:  BMJ       Date:  1989-01-14

7.  Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease.

Authors:  A G Røseth; P N Schmidt; M K Fagerhol
Journal:  Scand J Gastroenterol       Date:  1999-01       Impact factor: 2.423

8.  Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis.

Authors:  W J Sandborn; W J Tremaine; K W Schroeder; B L Steiner; K P Batts; G M Lawson
Journal:  Am J Gastroenterol       Date:  1993-05       Impact factor: 10.864

Review 9.  Neutrophils, nitrogen oxides, and inflammatory bowel disease.

Authors:  M B Grisham; T Yamada
Journal:  Ann N Y Acad Sci       Date:  1992       Impact factor: 5.691

10.  Intensive intravenous treatment of ulcerative colitis.

Authors:  G Järnerot; P Rolny; H Sandberg-Gertzén
Journal:  Gastroenterology       Date:  1985-11       Impact factor: 22.682
View more
  19 in total

1.  Leukocytapheresis (LCAP) for management of fulminant ulcerative colitis with toxic megacolon.

Authors:  Koji Sawada; Akimitsu Egashira; Kunio Ohnishi; Ken Fukunaga; Takeshi Kusaka; Takashi Shimoyama
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

2.  Leukocyte removal therapy before surgery in ulcerative colitis.

Authors:  Toshiyuki Matsui
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

3.  Leukocyte removal therapy for ulcerative colitis does not affect postoperative complications.

Authors:  Hiroki Ikeuchi; Takehira Yamamura; Masato Kusunoki; Hiroki Nakano; Motoi Uchino; Mitsuhiro Nakamura; Masafumi Noda; Hidenori Yanagi; Takayuki Matsumoto
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

4.  Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study.

Authors:  V Muratov; J Lundahl; A K Ulfgren; K Elvin; I Fehrman; N Ahlborg; A Ost; N Hittel; A Saniabadi; R Löfberg
Journal:  Int J Colorectal Dis       Date:  2006-03-15       Impact factor: 2.571

Review 5.  Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis.

Authors:  Hiroyuki Hanai
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

6.  Clinical effectiveness of selective granulocyte, monocyte adsorptive apheresis with the Adacolumn device in ulcerative colitis.

Authors:  Brigitte Habermalz; Stefan Sauerland
Journal:  Dig Dis Sci       Date:  2009-06-11       Impact factor: 3.199

7.  Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis.

Authors:  Hiroyuki Hanai; Takayuki Iida; Masami Yamada; Yoshihiko Sato; Ken Takeuchi; Tatsuo Tanaka; Kenji Kondo; Masataka Kikuyama; Yasuhiko Maruyama; Yasushi Iwaoka; Akiko Nakamura; Kazuhisa Hirayama; Abby R Saniabadi; Fumitoshi Watanabe
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

8.  Complement activation is involved in biological responses to leukocyte adsorptive apheresis.

Authors:  Shoichi Nishise; Yuji Takeda; Hiroaki Takeda; Katsuyoshi Ishihama; Tadahisa Fukui; Sumio Kawata
Journal:  Dig Dis Sci       Date:  2006-04-27       Impact factor: 3.199

9.  Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis.

Authors:  Hiroyuki Hanai; Ken Takeuchi; Takayuki Iida; Nobuhito Kashiwagi; Abby R Saniabadi; Isao Matsushita; Yoshihiko Sato; Naoki Kasuga; Toshihiro Nakamura
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

10.  Leukocyte apheresis in the management of ulcerative colitis.

Authors:  Ahmed Helmy; Maheeba Abdulla; Ingvar Kagevi; Khalid Al Kahtani
Journal:  Saudi J Gastroenterol       Date:  2009 Oct-Dec       Impact factor: 2.485
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.